AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
BioLife Solutions Updates 2025 Revenue Guidance to $100-103mln, Reflecting 22-25% YoY Growth
ByAinvest
Thursday, Aug 7, 2025 5:08 pm ET1min read
BioLife Solutions, Inc. revised its earnings guidance for 2025, expecting revenue to be between $100.0 million and $103.0 million, a 22% to 25% increase from 2024. The guidance reflects a year-over-year growth of 24% to 26% for the Cell Processing platform revenue and a year-over-year growth of 3% to 15% for evo and Thaw platform revenue.
BioLife Solutions, Inc. (Nasdaq: BLFS) has revised its financial projections for 2025, forecasting revenue to range between $100.0 million and $103.0 million. This represents a 22% to 25% increase from the prior year, with a focus on growth across its Cell Processing and evo and Thaw platforms. The company expects cell processing revenue to grow by 24% to 26%, while evo and Thaw platform revenue is anticipated to increase by 3% to 15% [1].The revised guidance reflects strong performance in the second quarter of 2025, where cell processing revenue reached $23.0 million, up 28% year-over-year. This growth was driven by the company's biopreservation media (BPM) franchise, which saw continued strength across both direct and distributor channels. The company's media is embedded in 16 approved therapies and supports over 250 ongoing commercial trials, including over 30 in Phase III [1].
BioLife Solutions also reported a GAAP gross margin of 62% and a non-GAAP adjusted gross margin of 65% for the second quarter. The company expects gross margins to remain in the low 60% range (GAAP) and mid-60% range (non-GAAP) for the full year 2025. Additionally, the company aims to reduce its net loss and expand adjusted EBITDA margin compared to 2024 [1].
The company's earnings call and webcast are scheduled for today at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the webcast via the BioLife Solutions Investor Relations page or by dialing toll-free 1-833-630-0431 or 1-412-317-1808 for international callers [1].
References:
[1] https://www.prnewswire.com/news-releases/biolife-solutions-reports-second-quarter-2025-financial-results-302524721.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet